---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-080414"
form_type: "8-K"
ticker: "INM"
cik: "0001728328"
company_name: "InMed Pharmaceuticals Inc."
filed_at: "2026-07-22T20:28:22+00:00"
generated_at: "2026-07-22T20:29:09.773576+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Mentari raises additional $200M private placement; extends cash runway into 2029

## Summary
- Additional $200M private placement from Fairmount, ADAR1, Venrock, Blackstone, Janus Henderson, and other healthcare investors.
- Proceeds extend cash runway into 2029 and through Phase 2a readout for PACAP-targeted programs including MT-002.
- Post-merger, pre-Merger Mentari stockholders own ~98.85% of combined company; InMed shareholders ~1.15%; total shares ~601M.
- Private placement expected to close immediately prior to merger completion, concurrent with previously announced $290M placement.
- Combined company to operate as Mentari Therapeutics and trade on Nasdaq under a new ticker symbol.

## SEC filing metadata
- accession: 0001213900-26-080414
- form_type: 8-K
- ticker: INM
- cik: 0001728328
- company_name: InMed Pharmaceuticals Inc.
- filed_at: 2026-07-22T20:28:22+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1728328/000121390026080414/0001213900-26-080414-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1728328/000121390026080414/ea0298644-8k425_inmed.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-080414
- JSON: https://secwatch.observer/filing/0001213900-26-080414.json
- Plain text: https://secwatch.observer/filing/0001213900-26-080414.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.